Girard Armand's Form 4 filing
Crescent Biopharma, Inc.CBIO · filed Mar 10, 2022
- Accession no.
- 0001209191-22-017968
- Filed
- Mar 10, 2022
- Trade date
- Mar 9, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $2.55K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Girard ArmandCIK 0001769636 | Officer (SVP, Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2022 | Common Stock | SSaleDisposed | −2,339 | $1.09F2 | −$2,549.51 | 22,661 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.11 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.